Biological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified.
DrugDrug NameDrug Indication
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00048Collagenase clostridium histolyticumUsed to promote debridement of necrotic tissue in the treatment of severe burns and dermal ulcers including decubitus ulcers.
DB00070Hyaluronidase (ovine)For increase of absorption and distribution of other injected drugs and for rehydration.
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB00103Agalsidase betaFor treatment of Fabry's disease (alpha-galactosidase A deficiency)
DB01272Alglucosidase alfaFor the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
DB05099AncrodAncrod is indicated for the treatment of deep vein thrombosis (DVT), central retinal branch vein thrombosis, pripaism, pulmonary hypertension of embolic origin, embolism after insertion of prosthetic cardiac valves, rethrombosis after thrombolytic therapy, rethrombosis after vascular surgery, and prevention of DVT after repair of a fractured neck of a femur.
DB06752ChymopapainChymopapain is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelography.[A32687] A disc herniation occurs when the outer portion of the spinal disc breaks down and the inner portion (nucleus pulposus) leaks out pressing surrounding nerves and leading to irradiating pain.[L2496] The chemonucleolysis is a non-surgical treatment that involves the injection of an enzyme to dissolve the nucleus pulposus.[L2482]
DB06760SacrosidaseFor the treatment of congenital sucrose-isomaltase deficiency (CSID).
DB09375ChymotrypsinNo therapeutic indications.
DB11237TrypsinNot Available
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00053ImigluceraseFor the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
DB00088AlgluceraseFor the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
DB01271IdursulfaseFor the treatment of Hunter syndrome in adults and children ages 5 and older.
DB01279GalsulfaseFor the treatment of adults and children with Mucopolysaccharidosis VI.
DB08876Taliglucerase alfaFor the treatment of adult Type 1 Gaucher disease.
DB09051Elosulfase alfaVimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
DB09105Asfotase alfaIndicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).
DB11563Sebelipase alfaSebelipase alfa is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.
DB05254FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DB13197KallidinogenaseNot Available
DB13199BrinaseNot Available
DB13281BromelainsNot Available
DB13646SaruplaseNot Available
DB00003Dornase alfaUsed as adjunct therapy in the treatment of cystic fibrosis.
DB00049RasburicaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
DB00090LaronidaseFor the treatment of mucopolysaccharidosis
DB06720Velaglucerase alfaVelaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
DB13761TilactaseTilactase is indicated for the symptomatic treatment of lactose intolerance in infants and older patients requiring a parenteral nutrition or fluid diet.[L2338] Lactose intolerance occurs when there is an existence of an inability to break down lactose which is commonly found in dairy products. This inability occurs when the lactase levels are reduced and thus there is no via to digest and break down the lactose. The undigested lactose moves into the large intestine where normal flora bacteria can interact with it and cause bloating, gas and diarrhea.[A32592]
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00023Asparaginase Escherichia coliIndicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) [FDA Label].
DB00036Coagulation factor VIIa Recombinant HumanFor treatment of hemorrhagic complications in hemophilia A and B
DB00042Botulinum Toxin Type BFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
DB00059PegaspargaseFor treatment of acute lymphoblastic leukemia
DB00061PegademaseFor treatment of adenosine deaminase deficiency
DB00083Botulinum toxin type AFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
DB00085PancrelipaseThe use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.[A32721, A32736] Pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas. Once established, pancreatic insufficiency results in malnutrition, weight loss, and steatorrhea.[A32723]
DB00640AdenosineUsed as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
DB04907Sitimagene ceradenovecIntended for the treatment of brain cancer.
DB04919AlfimepraseAlfimeprase is being evaluated as a potential treatment for acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB04950RanpirnaseFor the treatment of various forms of cancer.
DB05321PEG-uricaseInvestigated for use/treatment in hyperuricemia.
DB05330ALTU-135Investigated for use/treatment in cystic fibrosis and pancreatic disorders.
DB05584PraconaseInvestigated for use/treatment in spinal cord injuries.
DB05768Alkaline PhosphataseInvestigated for use/treatment in ulcerative colitis.
DB06245LanoteplaseInvestigated for use/treatment in myocardial infarction.
DB06326LatiglutenaseInvestigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.
DB06592PegargiminaseInvestigated for use/treatment in melanoma and hepatocellular carcinoma.
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB08839SerotoninNot Available
DB08885AfliberceptThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
DB08888OcriplasminOcriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
DB08898GlucarpidaseUsed in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (> 1 micromole per liter).
DB09005BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
DB09208PegloticaseFor the treatment of chronic gout in adult patients refractory to conventional therapy.
DB11065Pancrelipase amylasePlease refer to [DB00085].
DB11193PapainNo FDA-approved therapeutic indications.
DB11300ThrombinBovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. Additionally, topical bovine thrombin can also be used in combination with an absorbable gelatin sponge, USP [FDA Label].
DB11643Recombinant Cholera Toxin B SubunitNot Available
DB11668Rusalatide acetateNot Available
DB11690VonapanitaseNot Available
DB12249Stem bromelainThe primary medical purpose for which stem bromelain (SB) is currently indicated for is the removal of eschar in adults with deep partial- and full-thickness thermal burns [FDA Label]. Besides this official indication, however, it is also believed that SB may be used as a treatment for several other purposes as well, including cardiovascular health, osteoarthritis, autoimmunity, blood clotting, diarrhea, cancer, surgery, and debridement - although the specific mechanisms of action for these indications remain to be elucidated [A27198].
DB12409Vatreptacog alfaNot Available
DB12684AviscumineNot Available
DB12726MonteplaseNot Available
DB12835Olipudase alfaNot Available
DB12862Glucose OxidaseNot Available
DB12909Factor XIII (human)Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA Label].
DB13131SerrapeptaseNot Available
DB13198PepsinUsed as a pancreatic enzyme replacement in pancreatic insufficiency [L2357]. It is intended to mimic naturally produced human pepsin [L2360]. Pepsin powder is prepared from the gastric mucosa of pigs, cattle or sheep [L2367]. In the laboratory, it is primarily used for the unspecific hydrolysis of proteins and peptides in acidic media. In addition, it provides limited hydrolysis of native immunoglobulins, yielding biologically active fragments [L2353]. In certain supplements, pepsin may be combined with betaine and HCl (hydrochloric acid) to aid in digestion in various gastrointestinal conditions [L2360], [L2352].
DB13260LysozymeNot Available
DB13995Ferric pyrophosphate citrateFerric pyrophosphate citrate is indicated for the treatment of iron loss or iron deficiency to maintain hemoglobin and to reduce the prescribed dose of erythropoiesis-stimulating agent (ESA) required to maintain desired hemoglobin levels.[L1423] Iron deficiency appears when the dietary intake does not meet the body's requirement or when there is chronic external blood loss. During acute blood loss, body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis. But when the altered homeostasis remains for weeks to months then some supplement is needed. Some causes of iron deficiency include ectoparasitism, endoparasitism, hematuria, epistaxis, hemorrhagic skin, coagulopathy, thrombocytopenia, thrombocytopathia and gastrointestinal hemorrhage.[A31984]
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB09551DesoxyribonucleaseNot Available
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB00058Alpha-1-proteinase inhibitorFor chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
DB14562Andexanet alfaAndexanet alfa is indicated for patients treated with [rivaroxaban] and [apixaban], when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding [L3725]. Andexxa has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban and rivaroxaban [L3725].
DB09379SutilainSutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.[T169]
DB14730Calaspargase pegolThis drug is is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years [FDA label]. The pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL [L4890]. The FDA approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL when administering calaspargase, 2500 U/m2 intravenously, at 3-week intervals.
DB06651DiaPep 277Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
DB14740HyaluronidaseNot Available
DB12366Vestronidase alfaIndicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
DB12374Velmanase alfaNot Available
DB13173Cerliponase alfaCerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease to decelerate the progressive motor function decline in patients 3 years of age and older. CLN2 disease is a form of Batten disease, a rare inherited neurodegenerative disorder and is associated with seizures, ataxia, rapid loss of language and motor functions, blindness, and early death [L755]. It is caused by the lack the lysosomal enzyme tripeptidyl peptidase-1 (TPP1) and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system.
DB14988DalanterceptNot Available
DB15329NattokinaseNot Available
DB15336Valanafusp alfaNot Available
DB11572Thrombin alfaIndicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age [FDA Label]. Additionally, thrombin alfa can be used in conjunction with an absorbable gelatin sponge, USP [FDA Label].
DB12839PegvaliasePegvaliase is indicated for the management of phenylketonuria (PKU) in adult patients who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
DB15331Vocimagene amiretrorepvecNot Available
DrugDrug NameTargetType
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00048Collagenase clostridium histolyticumCollagen alpha-1(I) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-1(II) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-1(III) chaintarget
DB00048Collagenase clostridium histolyticumCollagen alpha-2(I) chaintarget
DB00070Hyaluronidase (ovine)Transforming growth factor beta-1target
DB00070Hyaluronidase (ovine)Serum albumincarrier
DB00070Hyaluronidase (ovine)Hyaluronantarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00103Agalsidase betaGlobotriaosylceramidetarget
DB01272Alglucosidase alfaCation-dependent mannose-6-phosphate receptortarget
DB01272Alglucosidase alfaGlycogentarget
DB05099AncrodFibrinogen alpha chaintarget
DB06752ChymopapainBone marrow proteoglycantarget
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB01271IdursulfaseDermatan sulfatetarget
DB01271IdursulfaseHeparan sulfatetarget
DB01279GalsulfaseDermatan sulfatetarget
DB08876Taliglucerase alfaGlucocerebrosidetarget
DB09051Elosulfase alfaN-acetylgalactosamine-6-sulfataseenzyme
DB09105Asfotase alfaSphingosine 1-phosphate receptor 1target
DB09105Asfotase alfaPyrophosphatetarget
DB05254FibrinolysinPlasminogen activator inhibitor 1target
DB05254FibrinolysinUrokinase-type plasminogen activatortarget
DB00003Dornase alfaDNAtarget
DB00049RasburicaseUric acidtarget
DB00090LaronidaseIduronic acidtarget
DB06720Velaglucerase alfaGlucosylceramidasetarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00023Asparaginase Escherichia coliL-asparaginetarget
DB00023Asparaginase Escherichia coliThyroxine-binding globulincarrier
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 1target
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 2target
DB00042Botulinum Toxin Type BSynaptotagmin-2target
DB00059PegaspargaseThyroxine-binding globulincarrier
DB00061PegademaseGrowth factor receptor-bound protein 2target
DB00083Botulinum toxin type ASynaptosomal-associated protein 25target
DB00083Botulinum toxin type ARho-related GTP-binding protein RhoBtarget
DB00085PancrelipaseDietary fattarget
DB00085PancrelipaseDietary proteintarget
DB00085PancrelipaseDietary starchtarget
DB00640AdenosineAdenosine receptor A3target
DB00640AdenosineAdenosine deaminaseenzyme
DB00640AdenosineAdenosine kinaseenzyme
DB00640AdenosineAdenosine receptor A1target
DB00640AdenosineAdenosine receptor A2atarget
DB00640AdenosineAdenosine receptor A2btarget
DB00640AdenosineSolute carrier family 28 member 3transporter
DB04919AlfimepraseFibrinogen alpha chaintarget
DB04919AlfimepraseFibrinogen beta chaintarget
DB05321PEG-uricaseUric acid degradation bifunctional proteintarget
DB06245LanoteplaseUrokinase plasminogen activator surface receptortarget
DB06245LanoteplaseFibrinogen alpha chaintarget
DB06245LanoteplaseLaminin subunit alpha-5target
DB06245LanoteplaseCoagulation factor Xtarget
DB06245LanoteplasePlasminogen activator inhibitor 2target
DB06245LanoteplaseKeratin, type II cytoskeletal 8target
DB06245LanoteplaseAnnexin A2target
DB06245LanoteplaseLaminin subunit beta-1target
DB06245LanoteplaseLaminin subunit gamma-1target
DB06245LanoteplaseLaminin subunit alpha-1target
DB06245LanoteplaseProlow-density lipoprotein receptor-related protein 1target
DB06245LanoteplaseLaminin subunit alpha-3target
DB08839SerotoninSolute carrier family 22 member 2transporter
DB08839SerotoninSodium-dependent serotonin transportertarget
DB08839Serotonin5-hydroxytryptamine receptor 2Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Atarget
DB08839Serotonin5-hydroxytryptamine receptor 3Btarget
DB08839SerotoninSynaptic vesicular amine transportertarget
DB08885AfliberceptVascular endothelial growth factor Atarget
DB08885AfliberceptPlacenta growth factortarget
DB08885AfliberceptVascular endothelial growth factor Btarget
DB09208PegloticaseUric acidtarget
DB11065Pancrelipase amylaseDietary starchtarget
DB11193PapainToll-like receptor 4target
DB11300ThrombinProteinase-activated receptor 1target
DB11300ThrombinProteinase-activated receptor 4target
DB11300ThrombinCoagulation factor XItarget
DB11300ThrombinCoagulation factor XIII A chaintarget
DB11300ThrombinCoagulation factor XIII B chaintarget
DB11300ThrombinFibrinogen alpha chaintarget
DB11300ThrombinFibrinogen beta chaintarget
DB11300ThrombinFibrinogen gamma chaintarget
DB11300ThrombinCoagulation factor Vtarget
DB11300ThrombinCoagulation factor VIIItarget
DB13995Ferric pyrophosphate citrateFerritin light chaintarget
DB13995Ferric pyrophosphate citrateFerritin heavy chaintarget
DB13995Ferric pyrophosphate citrateHemoglobin subunit alphatarget
DB13995Ferric pyrophosphate citrateHemoglobin subunit betatarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB00058Alpha-1-proteinase inhibitorNeutrophil elastasetarget
DB14562Andexanet alfaTissue factor pathway inhibitortarget
DB09379SutilainNecrotic Tissuetarget
DB14730Calaspargase pegolL-asparaginetarget
DB13173Cerliponase alfaCation-independent mannose-6-phosphate receptortarget
DB11572Thrombin alfaCoagulation factor XItarget
DB11572Thrombin alfaCoagulation factor VIIItarget
DB11572Thrombin alfaCoagulation factor Vtarget
DB11572Thrombin alfaCoagulation factor XIII A chaintarget
DB11572Thrombin alfaCoagulation factor XIII B chaintarget
DB11572Thrombin alfaFibrinogen alpha chaintarget
DB11572Thrombin alfaFibrinogen beta chaintarget
DB11572Thrombin alfaFibrinogen gamma chaintarget